Hypereosinophilia driven by GM-CSF in large-cell carcinoma of the lung

Lammel, Verena; Stoeckle, Christina; Padberg, Barbara; Zweifel, Roland; Kienle, Dirk; Reinhart, Walter H.; Simon, Hans‐Uwe

doi:10.1016/j.lungcan.2012.02.014

Cited by 33 publications

(27 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In these patients, we could demonstrate that GM‐CSF was derived from large‐cell carcinomas of the lung. One of these cases has been reported elsewhere .…”

Section: Resultsmentioning

confidence: 92%

CD8⁺ T cells producing IL-3 and IL-5 in non-IgE-mediated eosinophilic diseases

Stoeckle

Simon

2013

Allergy

View full text Add to dashboard Cite

The cytokines IL-5, IL-3, and GM-CSF are crucial for eosinophil development, survival, and function. To better understand their role in non-IgE-mediated eosinophilic diseases, we investigated plasma levels of these cytokines as well as cytokine expression in peripheral blood T cells. While we did not find any evidence for an involvement of T-cell-derived GM-CSF, some of these patients did show an increased proportion of IL-5- or IL-3-producing CD4(+) T cells. However, in a significant proportion of patients, IL-5-producing CD8(+) T cells, so-called Tc2 cells, which in healthy donors can only be detected at very low levels, were prominent. Furthermore, increased IL-3 production by CD8(+) T cells was also observed, strongly supporting the notion that CD8(+) T cells, not just CD4(+) T cells, must also be considered as a potential source of the cytokines promoting eosinophilia.

show abstract

“…In these patients, we could demonstrate that GM‐CSF was derived from large‐cell carcinomas of the lung. One of these cases has been reported elsewhere .…”

Section: Resultsmentioning

confidence: 92%

CD8⁺ T cells producing IL-3 and IL-5 in non-IgE-mediated eosinophilic diseases

Stoeckle

Simon

2013

Allergy

View full text Add to dashboard Cite

show abstract

“…1 Complications from leukemoid reaction chiefly result from increased blood viscosity. In cases where eosinophils are the predominant cell type, hydroxyurea has been shown to be beneficial (in one report, a decreased cell count from 120,000 to < 30,000/mL).…”

Section: Discussionmentioning

confidence: 99%

Paraneoplastic Leukemoid Reaction in Solid Tumors

Chakraborty

Keenportz

Woodward

et al. 2015

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Leukemoid reaction is defined as leucocytosis >50,000/μL. When it occurs in association with a malignancy, and infection or leukemia has been ruled out, it is termed as paraneoplastic leukemoid reaction. A patient presented with fatigue, generalized weakness, and abdominal distension and was incidentally noted to have a white blood cell count of 139,000/μL. Leukemia was ruled out by peripheral smear and flow cytometry. Computed tomography-guided biopsy of thickened omentum revealed poorly differentiated metastatic carcinoma. He died 3 days after admission with a peak white blood cell count of 180,000/μL. Previous reports and pathophysiology of paraneoplastic leukemoid reaction are reviewed.

show abstract

“…Primary and metastatic lung cancers are by far the most frequently occurring type of malignancy driven by the ectopically secreted G‐/GM‐CSF . Different histopathological types of a non‐small‐cell lung cancer (NSCLC) comprise a majority of cytokine‐producing lung tumors although a case of G‐CSF‐secreting lung sarcoma has also been described .…”

Section: Tumors Secreting G‐/gm‐csfmentioning

confidence: 99%

A role for G‐CSF and GM‐CSF in nonmyeloid cancers

Aliper¹,

et al. 2014

View full text Add to dashboard Cite

Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) modulate progression of certain solid tumors. The G-CSF- or GM-CSF-secreting cancers, albeit not very common are, however, among the most rapidly advancing ones due to a cytokine-mediated immune suppression and angiogenesis. Similarly, de novo angiogenesis and vasculogenesis may complicate adjuvant use of recombinant G-CSF or GM-CSF thus possibly contributing to a cancer relapse. Rapid diagnostic tools to differentiate G-CSF- or GM-CSF-secreting cancers are not well developed therefore hindering efforts to individualize treatments for these patients. Given an increasing utilization of adjuvant G-/GM-CSF in cancer therapy, we aimed to summarize recent studies exploring their roles in pathophysiology of solid tumors and to provide insights into some complexities of their therapeutic applications.

show abstract

Hypereosinophilia driven by GM-CSF in large-cell carcinoma of the lung

Cited by 33 publications

References 11 publications

CD8⁺ T cells producing IL-3 and IL-5 in non-IgE-mediated eosinophilic diseases

CD8⁺ T cells producing IL-3 and IL-5 in non-IgE-mediated eosinophilic diseases

Paraneoplastic Leukemoid Reaction in Solid Tumors

A role for G‐CSF and GM‐CSF in nonmyeloid cancers

Contact Info

Product

Resources

About

Hypereosinophilia driven by GM-CSF in large-cell carcinoma of the lung

Cited by 33 publications

References 11 publications

CD8+ T cells producing IL-3 and IL-5 in non-IgE-mediated eosinophilic diseases

CD8+ T cells producing IL-3 and IL-5 in non-IgE-mediated eosinophilic diseases

Paraneoplastic Leukemoid Reaction in Solid Tumors

A role for G‐CSF and GM‐CSF in nonmyeloid cancers

Contact Info

Product

Resources

About

CD8⁺ T cells producing IL-3 and IL-5 in non-IgE-mediated eosinophilic diseases

CD8⁺ T cells producing IL-3 and IL-5 in non-IgE-mediated eosinophilic diseases